InicioWXXWY • OTCMKTS
add
Wuxi Biologics Cayman ADR
Cierre anterior
4,14 $
Intervalo diario
4,07 $ - 4,25 $
Intervalo anual
2,58 $ - 13,25 $
Cap. bursátil
70,05 mil M HKD
Volumen medio
123,75 mil
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (CNY) | jun 2024info | Cambio interanual |
|---|---|---|
Ingresos | 4287,11 M | 0,97 % |
Gastos operativos | 765,14 M | 21,62 % |
Ingresos netos | 749,54 M | -33,86 % |
Margen de beneficio neto | 17,48 | -34,51 % |
Beneficios por acción | — | — |
EBITDA | 1236,50 M | -13,32 % |
Tipo impositivo efectivo | 11,36 % | — |
Balance general
Activos totales
Responsabilidades totales
| (CNY) | jun 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 9528,68 M | 9,60 % |
Activos totales | 56,11 mil M | 7,60 % |
Responsabilidades totales | 11,46 mil M | -12,46 % |
Patrimonio total | 44,64 mil M | — |
Acciones en circulación | 4151,36 M | — |
Precio-valor contable | 0,42 | — |
Rentabilidad económica | 4,05 % | — |
Retorno sobre capital | 4,62 % | — |
Flujo de caja
Variación neta del flujo de caja
| (CNY) | jun 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | 749,54 M | -33,86 % |
Efectivo de operaciones | 651,06 M | -52,65 % |
Efectivo de inversión | -191,26 M | 75,93 % |
Efectivo de financiación | -737,79 M | -684,70 % |
Variación neta del flujo de caja | -258,16 M | -153,79 % |
Flujo de caja libre | 350,65 M | 52,56 % |
Información sobre la empresa
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Director ejecutivo
Fundación
2010
Sitio web
Empleados
12.435
